Skip to main content
. 2023 Nov 16;209(6):631–633. doi: 10.1164/rccm.202310-1815VP

Figure 1.

Figure 1.

(A) Boxplot showing differences in influenza-associated pulmonary aspergillosis (IAPA) or coronavirus disease (COVID-19)-associated pulmonary aspergillosis (CAPA) incidence between observational studies that did not (n = 36) versus those that did (n = 13) report the number of all included patients who received BAL sampling. Blue and orange dots represent studies investigating patients with COVID-19 and influenza, respectively. P value was calculated with Mann-Whitney U test. (B) Boxplot showing the differences in IAPA or CAPA incidence between studies with <50% versus studies with >50% of all included patients having received a BAL sampling. Only observational studies that unequivocally reported the number of all included patients in whom at least one BAL sampling was performed were included in this analysis. Blue and orange dots represent studies investigating patients with COVID-19 and influenza, respectively. P value was calculated with Mann-Whitney U test.